Skip to main content
. 2013 Aug 7;2(9):655–666. doi: 10.5966/sctm.2013-0039

Figure 4.

Figure 4.

In vivo efficacy of CRAd-Survivin-pk7 (CRAd-S-pk7)-loaded NSCs and XRT-TMZ treatment against human-derived glioma xenografts. Intracranial GBM43 (3.5 × 105 cells per animal) was established, and the animals were treated for 5 consecutive days beginning on day 6 after tumor cell implantation. (A): Survival of animals treated with escalating doses of intraperitoneally administered TMZ (0, 5, 10, or 30 mg/kg). (B): Survival of animals treated with XRT (2 Gy) or a combination of XRT (2 Gy) and TMZ (2.5, 5, 10, or 30 mg/kg). (C): Survival of animals treated with the optimized dose of 2 Gy XRT and 5 mg/kg TMZ in addition to 5 × 105 or 3 × 106 NSCs loaded with 50 infectious units of CRAd-S-pk7. The addition of 5 × 105 or 3 × 106 loaded NSCs to XRT-TMZ treatment increased the median survival of glioma-bearing mice by 7 and 11 days, respectively. *, p < .05; **, p < .01; ***, p < .001. Abbreviations: ND, not determined; ns, no significance; NSC, neural stem cell; TMZ, temozolomide; XRT, radiation therapy.